Literature DB >> 7994444

Kidneys and primary hypertension--initiators, stabilizers or/and victim-aggravators?

B Folkow1.   

Abstract

As the kidneys so importantly contribute to longterm blood pressure control, and decisively to e.g. Goldblatt hypertension, it is often assumed that they are "prime movers" also in most variants of primary hypertension. The "pros and cons" of such a view are briefly discussed, and not least because strategies in therapy and preventive measures in man greatly depend on the nature, and major sites of expression, of the polygenetic predisposition. It is emphasized how the predisposing elements usually seem to exert their main influences via decidedly extra-renal parts of cardiovascular control systems in general, though soon leading to secondary "upward resetting" of the renal barostat function concerning both salt-water excretion and the renal pressure-regulating hormones. In SHR, for example, all proximal systemic resistance vessels, including the renal preglomerular ones, show an intrinsic tendency towards structural upward resetting quite early in life. Further, already early common variants of human primary hypertension, as well as SHR, exhibit an evidently "primary" central hyper-reactivity to psychosocial stimuli. Via neuro-hormonal pressor and growth-promoting effects such in principle extra-renal influences soon induce the same type of cardiovascular and renovascular structural upward resettings. Therefore the transfer of such kidneys to normotensive organisms here induces hypertension because of the prevailing preglomerular resistance increase, which easily gives the impression that these kidneys must have been the cause of hypertension in the donor organism as well.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7994444     DOI: 10.3109/08037059409102258

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  4 in total

Review 1.  Proteinuria: an underappreciated risk factor in cardiovascular disease.

Authors:  Julián Segura; Carlos Campo; Luis M Ruilope
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

2.  Nandrolone treatment decreases the level of rat kidney alpha(1B)-adrenoceptors.

Authors:  Staffan Uhlén; Jonas Lindblom; Anna Kindlundh; Paul Mugisha; Fred Nyberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-12       Impact factor: 3.000

Review 3.  Renal protection by antihypertensive therapy.

Authors:  Luis M Ruilope; Julian Segura
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

Review 4.  Renal dysfunction as a cardiovascular risk factor.

Authors:  Eberhard Ritz; Ralf Dikow; Luis M Ruilope
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.